Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$1.7 billion.

  • Akebia Therapeutics' Retained Earnings fell 96.07% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 96.07%. This contributed to the annual value of -$1.7 billion for FY2024, which is 431.4% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Retained Earnings stood at -$1.7 billion, which was down 96.07% from -$1.7 billion recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Retained Earnings ranged from a high of -$1.2 billion in Q1 2021 and a low of -$1.7 billion during Q4 2024
  • Moreover, its 5-year median value for Retained Earnings was -$1.6 billion (2023), whereas its average is -$1.6 billion.
  • As far as peak fluctuations go, Akebia Therapeutics' Retained Earnings crashed by 4589.26% in 2021, and later crashed by 96.07% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Retained Earnings stood at -$1.5 billion in 2021, then fell by 6.44% to -$1.6 billion in 2022, then fell by 3.33% to -$1.6 billion in 2023, then decreased by 4.31% to -$1.7 billion in 2024, then grew by 0.41% to -$1.7 billion in 2025.
  • Its Retained Earnings stands at -$1.7 billion for Q3 2025, versus -$1.7 billion for Q2 2025 and -$1.7 billion for Q1 2025.